585 related articles for article (PubMed ID: 29549485)
1. Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer.
Soria F; Beleni AI; D'Andrea D; Resch I; Gust KM; Gontero P; Shariat SF
World J Urol; 2018 Nov; 36(11):1703-1709. PubMed ID: 29549485
[TBL] [Abstract][Full Text] [Related]
2. Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors.
Hwang I; Park I; Yoon SK; Lee JL
Clin Genitourin Cancer; 2020 Apr; 18(2):e122-e133. PubMed ID: 31837940
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy beyond progression in advanced renal cell carcinoma: a case report and review of the literature.
Rebuzzi SE; Bregni G; Grassi M; Damiani A; Buscaglia M; Buti S; Fornarini G
Immunotherapy; 2018 Sep; 10(13):1123-1132. PubMed ID: 30236027
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Programmed Cell Death-1 Inhibitor Therapy.
Zheng B; Shin JH; Li H; Chen Y; Guo Y; Wang M
Korean J Radiol; 2021 Mar; 22(3):366-375. PubMed ID: 33289356
[TBL] [Abstract][Full Text] [Related]
5. [Implications of TCGA Network Data on 2nd Generation Immunotherapy Concepts Based on PD-L1 and PD-1 Target Structures].
Peters I; Tezval H; Kramer MW; Wolters M; Grünwald V; Kuczyk MA; Serth J
Aktuelle Urol; 2015 Nov; 46(6):481-5. PubMed ID: 26560846
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy for renal cell carcinoma.
Bleumer I; Oosterwijk E; De Mulder P; Mulders PF
Eur Urol; 2003 Jul; 44(1):65-75. PubMed ID: 12814677
[TBL] [Abstract][Full Text] [Related]
7. Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.
Rouanne M; Roumiguié M; Houédé N; Masson-Lecomte A; Colin P; Pignot G; Larré S; Xylinas E; Rouprêt M; Neuzillet Y
World J Urol; 2018 Nov; 36(11):1727-1740. PubMed ID: 29855698
[TBL] [Abstract][Full Text] [Related]
8. Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors.
Iacovelli R; Ciccarese C; Bria E; Bracarda S; Porta C; Procopio G; Tortora G
Eur J Cancer; 2020 Sep; 136():195-203. PubMed ID: 32712550
[TBL] [Abstract][Full Text] [Related]
9. Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: A systematic review.
Queirolo P; Spagnolo F
Cancer Treat Rev; 2017 Sep; 59():71-78. PubMed ID: 28756306
[TBL] [Abstract][Full Text] [Related]
10. Emerging immunotherapy in advanced renal cell carcinoma.
Mendiratta P; Rini BI; Ornstein MC
Urol Oncol; 2017 Dec; 35(12):687-693. PubMed ID: 28889919
[TBL] [Abstract][Full Text] [Related]
11. Imaging response assessment of immunotherapy in patients with renal cell and urothelial carcinoma.
Weiss J; Notohamiprodjo M; Bedke J; Nikolaou K; Kaufmann S
Curr Opin Urol; 2018 Jan; 28(1):35-41. PubMed ID: 29083998
[TBL] [Abstract][Full Text] [Related]
12. Update of systemic immunotherapy for advanced urothelial carcinoma.
Gartrell BA; He T; Sharma J; Sonpavde G
Urol Oncol; 2017 Dec; 35(12):678-686. PubMed ID: 29079131
[TBL] [Abstract][Full Text] [Related]
13. Pseudoprogression and hyperprogression after checkpoint blockade.
Wang Q; Gao J; Wu X
Int Immunopharmacol; 2018 May; 58():125-135. PubMed ID: 29579717
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant therapy for advanced renal cell carcinoma.
Meissner MA; McCormick BZ; Karam JA; Wood CG
Expert Rev Anticancer Ther; 2018 Jul; 18(7):663-671. PubMed ID: 29707987
[TBL] [Abstract][Full Text] [Related]
15. [Tumor assessment in immune checkpoint inhibitor therapy : Tumor response, progression and pseudoprogression].
Foller S; Oppel-Heuchel H; Grimm MO
Urologe A; 2018 Nov; 57(11):1316-1325. PubMed ID: 30334063
[TBL] [Abstract][Full Text] [Related]
16. Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions.
Lalani AA; McGregor BA; Albiges L; Choueiri TK; Motzer R; Powles T; Wood C; Bex A
Eur Urol; 2019 Jan; 75(1):100-110. PubMed ID: 30327274
[TBL] [Abstract][Full Text] [Related]
17. Vaccine therapy in patients with renal cell carcinoma.
Van Poppel H; Joniau S; Van Gool SW
Eur Urol; 2009 Jun; 55(6):1333-42. PubMed ID: 19201522
[TBL] [Abstract][Full Text] [Related]
18. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy.
Stillebroer AB; Mulders PF; Boerman OC; Oyen WJ; Oosterwijk E
Eur Urol; 2010 Jul; 58(1):75-83. PubMed ID: 20359812
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers for immunotherapy in urological cancers.
Gust KM; Resch I; D'Andrea D
Curr Opin Urol; 2018 Jan; 28(1):25-28. PubMed ID: 29120910
[TBL] [Abstract][Full Text] [Related]
20. Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy.
Hodi FS; Ballinger M; Lyons B; Soria JC; Nishino M; Tabernero J; Powles T; Smith D; Hoos A; McKenna C; Beyer U; Rhee I; Fine G; Winslow N; Chen DS; Wolchok JD
J Clin Oncol; 2018 Mar; 36(9):850-858. PubMed ID: 29341833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
